Molecule

Drug Groups

approved; withdrawn

Description

An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem]

Indication

Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.

Pharmacology

Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.

Affected Organisms

Biotransformation

No active metabolites

Absorption

Rapidly absorbed. Absolute bioavailability is 90%.

Half Life

4-7 hours

Protein Binding

89-98%

External Links